retatrutide type 2 diabetes trial 2024 produces up to 30.3% weight loss in Phase 3 Phase 2 trial results demonstrate

This is when most researchers feel their best and when intense workouts, social meals, and demanding work schedules are most manageable

From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies

Its FDA-approved for treating type 2 diabetes and contains the same active ingredient as Ozempic and Wegovy injections

This is because using unauthorised medications can be unsafe due to unknown quality, dosing and risks